News & Updates

Supply chain disruptions have become the new normal. Recurring pandemic waves, inflation, trade jitters, and a war in Europe have done little to quell C-suite anxieties.  

Most pharma execs keeping an eye on the situation are looking for the off-ramp and a subsequent return to normal, but is this realistic? Will our supply chain troubles return to the shadows, or are we fated to endlessly fret over shortages, delays, and interruptions? Read More

Informa Markets colleagues explain the motivations behind CPHI’s rebrand. 

CPHI is a well-established leader in the pharma events space, uniting thousands of industry professionals across the world each year. Our goal has been, and continues to be, to create experiences that connect stakeholders from across the supply chain and result in meaningful partnerships. Read more.

The latest coronavirus updates and developments impacting the global pharmaceutical supply chain

29 June

Advisers to the US Food and Drug Administration have recommended a change to the design of COVID-19 booster vaccines this autumn in order to protect against the most recently circulating variants. The FDA's Vaccines and Related Biological Products Advisory Committee voted 19-2 that the next round of COVID booster shots should be effective against the Omicron variant. The FDA plans to decide on the design of the boosters by early July. Read more.

CPHI has launched its forward-looking pharma trend report for 2022 and it is now available to read on CPHI Online.

Via interviews with key industry experts, the report, which is sponsored by Baxter, outlines ten emerging trends which are likely to have the biggest impact on the pharmaceutical manufacturing and outsourcing sector over the next 12 months, as it takes stock of the notable events of 2021. Read more.

It would be disingenuous to claim 2019 was a revolutionary year for pharma as it continues its journey towards a patient-centric model.

As biopharma heads towards a new decade, extracting value from innovation remains a key theme in medicines development. 

Players in the pharmaceutical value chain will need to fully harness cutting-edge digital technologies such as artificial intelligence (AI) and cyber-security solutions to make greater efficiency...

South Africa and Kenya represent the best opportunities for pharmaceutical manufacturing firms thinking of investing in Sub-Saharan Africa, according to Martin Tronquit, Managing Partner at data...

Is the pharma industry making the most of AI’s potential when it comes to accelerating and enhancing pharmaceutical drug development? The utilisation of artificial intelligence (AI) by the pharmaceutical industry is gathering pace rapidly. The technology has evolved beyond simple neural networks and machine learning towards a deep learning approach geared at producing insights which should in theory enable better business decision making. Read more.

FDA approval of GW Pharmaceuticals’ Epidiolex® is widely considered to be a landmark in cannabinoid-derived drug development. Not only is Epidiolex® the first FDA-approved drug that contains a purified drug substance (cannabidiol) derived from the Cannabis sativa plant (marijuana), but it is also the first FDA approved drug for the treatment of patients with a rare and severe form of childhood epilepsy, Dravet syndrome. Read more.

Pipeline diversification, emerging therapies and shifting customer demands are the real dynamics reshaping the contract manufacturing market, according to experts. Almost every article written about contracting reports that demand for outsourced manufacturing services is growing and states that the CDMO sector is consolidating. Read more.

Empathy is the ability to understand another person’s feelings and perspectives. By taking the time to relate to others, you build trust,
encourage honesty and open up communication lines. Not only does this create an environment where everyone can fulfil their potential, it also provides far greater scope for innovation. Read more.